Kestra Medical Technologies (KMTS) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
28 Jul, 2026Executive summary
Annual meeting scheduled for September 9, 2026, with virtual participation available.
Shareholders are invited to vote on director elections and auditor ratification.
Proxy materials and annual report are accessible online or by request before August 26, 2026.
Voting matters and shareholder proposals
Election of three Class II directors to serve until the 2029 annual meeting or until successors are elected: Raymond W. Cohen, Kevin Reilly, and Traci S. Umberger.
Ratification of PricewaterhouseCoopers LLP as independent registered accounting firm for fiscal year ending April 30, 2027.
Proxyholders authorized to vote on other business as may properly come before the meeting.
Board of directors and corporate governance
Board recommends voting in favor of all director nominees and auditor ratification.
Latest events from Kestra Medical Technologies
- Shareholders will vote on director elections and auditor ratification, with strong governance in place.KMTS
Proxy filing28 Jul 2026 - Q4 revenue up 66%, FY26 revenue up 59%, FY27 guidance targets 44% growth.KMTS
Q4 202615 Jul 2026 - Rapidly scaling cardiac care platform addresses a $10B market with proven outcomes and expanding margins.KMTS
Company presentation14 Jul 2026 - Rapid sales force expansion and clinical innovation are fueling strong growth and market share gains.KMTS
Bank of America Global Healthcare Conference 202614 May 2026 - Double-digit growth fueled by clinical proof, innovation, and expanding commercial scale.KMTS
44th Annual J.P. Morgan Healthcare Conference13 Apr 2026 - Clinically proven WCD platform drives rapid growth in a $10B U.S. cardiac care market.KMTS
Company presentation18 Mar 2026 - Q3 FY26 revenue up 63% to $24.6M, gross margin 52.6%, and FY26 guidance raised to $93M.KMTS
Q3 202617 Mar 2026 - Innovative WCD platform drives rapid growth, margin expansion, and broad payor coverage.KMTS
Company presentation13 Jan 2026 - Q3 revenue up 82% to $15.1M, gross margin at 43.4%, and IPO proceeds boost growth outlook.KMTS
Q3 202527 Dec 2025